SMTI Q4 2025 Earnings Call Summary | Stock Taper
Logo
Pricing Sign Up Log In
SMTI

SMTI — Sanara MedTech Inc.

NASDAQ

Q4 2025 Earnings Call Summary

March 24, 2026

Sanara MedTech (SMTI) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

  • Full Year 2025 Performance:

    • Net revenue reached $103.1 million, a 19% increase year-over-year.
    • Gross margins improved by 200 basis points to 93%.
    • Adjusted EBITDA rose to $17 million, an 86% improvement.
    • Cash provided by operations was $6.8 million, up from $24,000 used in 2024.

  • Q4 2025 Performance:

    • Net revenue was $27.5 million, a 5% increase year-over-year (or 13% excluding prior year’s hurricane-related sales).
    • Gross profit increased by 7% to $25.7 million.
    • Operating income was $1.1 million, down from $2.3 million in Q4 2024, impacted by a $1.8 million impairment charge.
    • Net loss from continuing operations was $1.1 million, or $0.13 per diluted share.

2. Strategic Updates and Business Highlights

  • Commercial Strategy: Focused on three key initiatives:

    1. Strengthening relationships with independent distributors (over 450 contracted distributors by year-end).
    2. Expanding into new healthcare facilities (over 1,450 facilities served).
    3. Increasing adoption within existing facilities, with low surgeon penetration indicating growth potential.

  • Product Developments:

    • Secured an Innovative Technology contract from Vizient for the BIASURGE product, expanding access to 1,800 healthcare facilities.
    • Continued focus on clinical evidence with studies supporting CellerateRX and BIASURGE.
    • Progress on the OsStic product, expected to launch in Q1 2027.

3. Forward Guidance and Outlook

  • 2026 Revenue Guidance: Expected net revenue between $116 million and $121 million, representing 13% to 17% growth from 2025.
  • Q1 2026 Guidance: Anticipated net revenue of approximately $26.7 million to $27.2 million, a 14% to 16% increase year-over-year.

4. Bad News, Challenges, or Points of Concern

  • Operating Income Decline: Operating income decreased due to a noncash impairment charge and increased operating expenses.
  • Net Loss: The company reported a net loss for Q4, contrasting with a profit in the same quarter last year.
  • Dependency on Distributor Education: Growth from the Vizient contract may take time as the company needs to educate facilities about the product.
  • Competitive Pressures: The need to maintain and enhance clinical evidence to stay competitive in the surgical market.

5. Notable Q&A Insights

  • BIASURGE Growth: The Vizient contract is expected to significantly contribute to growth in 2026, although the company is cautious about quantifying the exact impact.
  • CellerateRX Reimbursement: The product is not subject to reimbursement risk, which is seen as a positive for its market position. The company plans to continue investing in clinical and economic studies to bolster its value proposition.
  • Focus on Core Business: Management emphasized a commitment to a focused approach as a pure-play surgical company, investing in sales and R&D to support growth.

Overall, Sanara MedTech demonstrated strong financial growth in 2025, with strategic initiatives aimed at expanding its market presence and product offerings. However, challenges such as operating income decline and the need for ongoing education in the market remain areas of concern.

← Q3 2025 Q1 2026 →